The UK biotech sector raised £3.5 billion in equity financing last year amid challenges, according to a BIA report.

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

As most followers of the PIMCO Dynamic Income Strategy fund (PDX) know, the rapid-growth trajectory of the fund has been ...

Analysts say outlook is good after uneven trading start; leaders Sabel and Pender see windfall from stock listing ...

Smithfield Foods was valued at $7.7 billion after its shares fell 3.2% on Tuesday, in a muted debut that might prompt other ...

HOUSTON (Reuters) - Federal regulators on Tuesday gave Venture Global LNG permission to introduce natural gas into the ...

Tuesday's Forbes Daily covers Chinese AI DeepSeek's impact on stock market, Boeing's earnings woes, Trump's military orders, ...

The oil-and-gas company said that full-year production for 2024 was 258,000 barrels of oil-equivalent a day, up around 40% on 2023. Santee Cooper said it is looking for proposals from companies ...

The fallout for Venture Global Inc., in the wake of a troubled initial public offering, accelerated amid a market selloff ...

Snag is, Cheniere’s two export terminals are already advanced enough to generate several billion dollars in cash flow, much of which is already flowing in dividends to shareholders. Venture Global is ...

(Reuters) -Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in ...

On , Beijing Time, Qiming Venture Partners' portfolio company HyperStrong, a leading provider of battery energy storage systems (BESS) in China, successfully debuted on the Shanghai Stock Exchange's ...